Achilles Therapeutics: Q1 Earnings Insights Achilles Therapeutics (NASDAQ:ACHL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Benzinga · May 10, 2022
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in CHIRON Phase 1/2a Trial for Advanced NSCLC Achilles Therapeutics plc (NASDAQ: ACHL) announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the Company's higher-dose VELOS™ Process 2 in the ongoing Phase I/IIa CHIRON clinical trial for the treatment of advanced non-small cell lung can Benzinga · May 9, 2022